EJ Lane
FiercePharma
Contact EJ
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by EJ:
Major postapproval study on Xarelto marks a first in patient numbers in Japan
The Japan leg of a major postmarketing study in Japan on Bayer's Xarelto set a milestone in patient numbers. → Read More
Calls grow for China to bring in newer HCV therapies
Calls are growing on China to speed up approvals for newer hepatitis C therapies as well as pricing access formulas. → Read More
Takeda Q1 earnings soar as plans to speed R&D rejig announced
Takeda Pharmaceutical said it would accelerate a reorganization of its R&D units in the U.S. and Japan to focus on the three therapy areas previously outlined. → Read More
Singapore's TauRx PhIII fails in mild to moderate Alzheimer's trial
A major Phase III clinical trial of a tau inhibitor aggregation therapy by Singapore's TauRx failed to meet its primary endpoint, though the work showed an identified subgroup with a statistically significant benefit as a monotherapy. → Read More
Singapore's TauRx slated to update on PhIII Alzheimer's trials
Singapore-based TauRx will update on Phase III studies of its tau aggregation inhibitor LMTX in a podium presentation at the Alzheimer’s Association International Conference in Toronto on July 27. → Read More
Suicide of Abbott rep in India raises questions on sales tactics
Reports that a sales representative at Abbott Laboratories in India cited work performance demands in a suicide note have reverberated among colleagues. → Read More
UPDATED: Indian drugmakers in the catbird seat for Crestor generics after AZ ruling
Indian firms Sun Pharmaceutical Industries, Aurobindo Pharma and Glenmark Pharmaceuticals are in the catbird seat on generics of AstraZeneca's Crestor. → Read More
Asia ground zero for Alcon turnaround plans with new China a focus
Asia is at the center of turnaround plans for the Alcon unit of Novartis with the new top executive suggesting spending needs to increase first. → Read More
J&J updates on Celltrion Remicade biosimilar in U.S. outlook with October date
Johnson & Johnson executives were a bit more cautious on the timing of a launch of a Remicade biosimilar from South Korea's Celltrion in the U.S. → Read More
India's Sun Pharma senior executives swap leadership roles
Sun Pharmaceutical has rejigged management in India and North America. → Read More
EMA to review Samsung Bioepis Humira biosim application
Samsung Bioepis received acceptance of a European Marketing Authorization application for a biosimilar of AbbVie's blockbuster Humira. → Read More
China's Changzhou Fangyuan plans trials on hard-to-make generic superbug antibiotic
Changzhou Fangyuan Pharma is ready for clinical trials in China to test its nearly decade-long work on a tricky-to-make semisynthetic, methicillin-resistant and gram-negative infection-fighting antibiotic. → Read More
South Korea's Hanmi eyes branded drugs, fast-paced R&D and China push to grow
Hanmi Pharmaceutical eyes branded drugs, fast-paced R&D and investment in China to get growth on track. → Read More
Plenty of room for healthcare insurance growth in China: EY
China's rapidly aging population and growing incidences of chronic diseases make it ripe for a boom in private health insurance. → Read More
Plenty of room for healthcare insurance growth in China: EY
China's rapidly aging population and growing incidences of chronic diseases make it ripe for a boom in private health insurance. → Read More
India is next stop for GSK sales and marketing overhaul
GlaxoSmithKline will bring its cleaned-up marketing and sales focus to India by following steps it took in China as it looks to implement globally a "New Way" in the wake of being hit with major fines. → Read More
India's Aurobindo eyes Teva generics for divestment in Allergan deal
Aurobindo Pharma wants to snap up some of the generics up for grabs from Teva Pharmaceutical Industries as it sells products to meet antitrust concerns so it can buy the generics business of Allergan. → Read More
India tweaks biosimilar guidelines to narrow waivers in clinical trials
India has tweaked its biosimilar approval guidelines from a draft and narrowed the scope to issue for waivers to run Phase III trials. → Read More
Japanese firms eye sale of patent-expired drugs to fund new blockbusters
Astellas Pharma and Shionogi are looking to sell branded drugs that have expired patents in Japan in a play to take the funds and invest in newer therapies or business lines. → Read More
Japan's latest approvals include Praluent in second PCSK9 inhibitor
Japan's Ministry of Health, Labor and Welfare granted marketing and manufacturing authorization for Praluent to Regeneron Pharmaceuticals and Sanofi, marking the second PCSK9 inhibitor nod in the country. → Read More